Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 17/20 | 0.53 |
| ▸ | ITGA5 | P08648 | 5/20 | 0.53 |
| ▸ | ITGA4 | P13612 | 13/20 | 0.50 |
| ▸ | ITGB7 | P26010 | 5/20 | 0.48 |
| ▸ | ITGA2 | P17301 | 1/20 | 0.48 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | NOS2 | P35228 | 1/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGAV | P06756 | 1/20 | 0.45 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4248263 | 0.93 | ITGB1 (0.55) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL4253009 | 0.91 | ITGB1 (0.54) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL8232468 | 0.91 | ITGB1 (0.54) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL18067854 | 0.87 | ITGB1 (0.53) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL18067856 | 0.87 | ITGB1 (0.49) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL18067868 | 0.86 | ITGB1 (0.55) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL4928013 | 0.86 | ITGB1 (0.54) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL8235253 | 0.84 | ITGB1 (0.52) | ITGB1ITGA5ITGA4ITGB7ITGA2 | |
| SCHEMBL4068087 | 0.84 | ITGB1 (0.70) | ITGB1ITGA5ITGA4ITGB3ITGAV | |
| SCHEMBL13726463 | 0.83 | ATM (0.59) | ITGB1ITGA4ITGB7ITGA2NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045521-A1 | PHENYLALANINE DERIVATIVES | ITGB5, ITGB1, ITGA2B | ITGB1 2/4885ITGA5 7/4885ITGA4 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.